PPT-An introduction to the EU Regulation

Author : aron472 | Published Date : 2024-11-26

Regulation EU 2017821 of the European Parliament and of the Council laying down supply chain due diligence obligations for Union importers of tin tantalum and tungsten

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "An introduction to the EU Regulation" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

An introduction to the EU Regulation: Transcript


Regulation EU 2017821 of the European Parliament and of the Council laying down supply chain due diligence obligations for Union importers of tin tantalum and tungsten their ores and gold originating from conflictaffected and highrisk areas. Personal use and regulation of marijuana 17 1 Purpose and findings 18 a I N THE INTEREST OF THE EFFICIENT USE OF LAW ENFORCEMENT 19 RESOURCES ENHANCING REVENUE FOR PUBLIC PURPOSES AND INDIVIDUAL 20 FREEDOM THE PEOPLE OF THE STATE OF OLORADO FIND AND 1 Introduction The consultation process carried out by the Department earlier this year was based on the broad principles that might inform the development of proposals for lobbying regulation. Fo COMMISSION REGULATION 583/2010 of 1 July 2010 implementing Directive 2009/65/EC of the European Parliament and of the Council as regards key investor information and conditions to be met when providi 1 RFU REGULATION 15 – AGE GRADE RUGBYEective from 1 August 2015 111111111111111 2 (b)U10s with U11s; and(c) In respect of Schools and Clubs with an insucient number of players, U9s can train an Impact on patient safety . – . with. . focus. on . supervision. Solveig Wiesener. Senior Adviser, MSc Risk management and societal safety. 19th EPSO meeting. The Norwegian Board of Health Supervision, Oslo . 1 1. Introduction Academic research on how bribes affect firm value has so far focused on detected bribery cases. Among detected and prosecuted bribery cases, a $1 bribe payment creates $11 firm valu Executive Functioning: Theory and Implications for Management. Russell A. Barkley, Ph.D.. Clinical Professor of Psychiatry. Medical University of South Carolina. Charleston, SC. ©. Copyright by Russell A. Barkley, Ph.D., 2012. Contents 2. Safeguarding and regulation 3. Safeguarding and Mental Health Act Operations 4. CQC and Ofsted joint inspections – safeguarding children 5. CQC’s role in local safeguarding Superannuation Circular No. I.A.1 Contents Objective Introduction Contributions General Types of contributions and when they can be accepted Contributions for members aged less Contributions Mini-Skills Presentation. NASP 2012 Annual Convention, Philadelphia. Elena Savina, PhD, Samantha . Tynan. , Ed.M., . Phoebe Wan, M.A., . Marlana. Ashe, . Ed.S. .. Combined-Integrated Doctoral Program in Clinical and School Psychology, James Madison University, VA . Eric A. Posner. University of Chicago Law School. 1. Overview. What is cost-benefit analysis (CBA)?. The role of CBA in agency regulation. Congress. Executive branch. Courts. 2. Overview, cont.. The Theory of CBA. [INSERT DATE HERE]. [NAME OF PRESENTER]. [TITLE OF PRESENTER]. [COMPANY NAME]. Falsified medicines – a real problem. 2. The Pharmaceutical Journal, 5. th. June 2014. Why we need a Directive . Falsified products still being found in legitimate medicines supply chain – major risk to patient safety. [INSERT DATE HERE]. [NAME OF PRESENTER]. [TITLE OF PRESENTER]. [COMPANY NAME]. Falsified medicines – a real problem. 2. The Pharmaceutical Journal, 5. th. June 2014. Why we need a Directive . Falsified products still being found in legitimate medicines supply chain – major risk to patient safety. [INSERT DATE HERE]. [NAME OF PRESENTER]. [TITLE OF PRESENTER]. [COMPANY NAME]. Falsified medicines – a real problem. 2. The Pharmaceutical Journal, 5. th. June 2014. Why we need a Directive . Falsified products still being found in legitimate medicines supply chain – major risk to patient safety.

Download Document

Here is the link to download the presentation.
"An introduction to the EU Regulation"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents